BE in hepatic impairment? [BE/BA News]

posted by nobody – 2019-08-30 07:29  – Posting: # 20530
Views: 160

Hello again!

Today I have to read this here:

https://www.fdanews.com/articles/192544-persion-petitions-fda-to-raise-the-safety-bar-for-extended-release-opioid

But the originator found differences in PK in mild/moderate hepatic impairment not worth any dose adjustment according to the current label and the differences as outlined in the FDA AssRep are unimpressive. I'm trying to figure out a formulation-related influence of hepatic function on BA/BE...

Lawyers looking for some work? How low can you go? Is that state-of-the-art in 2019?

Kindest regards, nobody

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,789 posts in 4,196 threads, 1,358 registered users;
online 11 (1 registered, 10 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 12:54 UTC

100% of all disasters are failures of design, not analysis.    Ronald G. Marks

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5